Company Number: 13667246

Analysis Date: 2025-07-20 11:53 UTC

1. Credit Opinion: CONDITIONAL APPROVAL
   Hanya Pharm Limited presents as a very small, micro-entity company with a single director and shareholder. The company shows positive net assets and working capital, indicating basic financial stability. However, the sharp decline in current assets and net assets from 2023 to 2024, alongside the director loan balance fluctuations, suggests some volatility in liquidity and cash flows. The unsecured, interest-free director loan with significant advances and repayments introduces some risk. The company’s micro size and limited operating history (incorporated 2021) warrant cautious credit extension, potentially with limits on exposure and monitoring conditions.

2. Financial Strength:

• Net assets decreased from £31,421 in 2023 to £24,062 in 2024, reflecting erosion of equity by approximately 23%.
• Current assets dropped markedly (£44,456 to £24,913), while current liabilities reduced substantially (£12,713 to £435), improving net current assets but possibly indicating less operational cash or receivables.
• Fixed assets are minimal and decreasing (£428 to £214), consistent with a service-oriented micro business with limited capital investment.
• The balance sheet shows positive net current assets (£24,478) and shareholders’ funds (£24,062), so the company is solvent at the balance sheet date but with shrinking capital base.

3. Cash Flow Assessment:

• The significant reduction in current assets (especially cash/debtors) may point to reduced cash inflows or higher cash outflows during the latest year.
• Director loan movements (net increase to £8,196 receivable) suggest reliance on director funding, which while helpful, is unsecured and repayable on demand—this is a liquidity risk factor.
• With current liabilities very low (£435), the company’s short-term obligations appear manageable, but the working capital reduction signals tighter liquidity.
• No audit or detailed cash flow statement is available, limiting insight into operating cash generation.

4. Monitoring Points:

• Track quarterly cash flow and working capital trends closely to detect emerging liquidity pressures.
• Review director loan balances and repayment patterns to assess potential financial stress or dependency on shareholder funding.
• Monitor profit and loss trends once available to confirm if net asset declines are due to operating losses or other factors.
• Watch for timely filing of accounts and confirmation statements to ensure regulatory compliance and transparency.
• Assess any changes in business scale or client diversification that might impact revenue stability.